Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted.

Slides:



Advertisements
Similar presentations
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Advertisements

Krinos M. Trokoudes, M. D. , Constantinos Pavlides, M. Sc
Demián Glujovsky, M.D., M.Sc., Cynthia Farquhar, M.D., M.P.H. 
Is the type of gonadotropin-releasing hormone suppression protocol for ovarian hyperstimulation associated with ectopic pregnancy in fresh autologous.
Quality of life and psychosocial and physical well-being among 1,023 women during their first assisted reproductive technology treatment: secondary outcome.
Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration  Jean-noêl Hugues,
Patient and cycle characteristics predicting high pregnancy rates with single-embryo transfer: an analysis of the Society for Assisted Reproductive Technology.
The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,
Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,
Extremities of body mass index and their association with pregnancy outcomes in women undergoing in vitro fertilization in the United States  Jennifer.
Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.
1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.
Michael M. Alper, M.D.  Fertility and Sterility 
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials  Ana Cobo, Ph.D., César Diaz, M.D. 
Adherence compounds in embryo transfer media for assisted reproductive technologies: summary of a Cochrane review  Stephan Bontekoe, M.D., Neil Johnson,
Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study  Nicole Hope, M.B., B.S., Hon., Luk.
Is frozen embryo transfer cycle associated with a significantly lower incidence of ectopic pregnancy? An analysis of more than 30,000 cycles  Bo Huang,
Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for.
Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy  Ewa Nowak-Markwitz,
The relative contribution of assisted reproductive technologies and ovulation induction to multiple births in the United States 5 years after the Society.
Live birth of twins derived from zona-free oocytes
Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D. 
How old is too old? Challenges faced by clinicians concerning age cutoffs for patients undergoing in vitro fertilization  Robert L. Klitzman, M.D.  Fertility.
Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles  Tsung-Hsien.
Robert F. Casper, M.D.  Fertility and Sterility 
Association of the very early rise of human chorionic gonadotropin with adverse outcomes in singleton pregnancies after in vitro fertilization  Christopher.
Looking back: egg donors' retrospective evaluations of their motivations, expectations, and experiences during their first donation cycle  Nancy J. Kenney,
Influence of acupuncture stimulation on pregnancy rates for women undergoing embryo transfer  Caroline Smith, Ph.D., Meaghan Coyle, B.Hlth.Sc. (Acup.),
Efficacy and safety of frozen-thawed embryo transfer in women aged 35 to 42 years from the PURSUE randomized clinical trial  Robert Boostanfar, M.D.,
Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.
A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone 
Sean Ackerman, M. D. , Julia Wenegrat, M. A. , David Rettew, M. D
Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.
The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization: a systematic review and meta-analysis 
Programming the endometrium for deferred transfer of cryopreserved embryos: hormone replacement versus modified natural cycles  Eva R. Groenewoud, M.D.,
Clomiphene citrate at 50: the dawning of assisted reproduction
Using the Society for Assisted Reproductive Technology Clinic Outcome System morphological measures to predict live birth after assisted reproductive.
Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist  N. Rollene, M. Amols, S. Hudson,
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Effect of letrozole at 2. 5 mg or 5
Gonadotropin-releasing hormone antagonist use is associated with increased pregnancy rates in ovulation induction–intrauterine insemination to in vitro.
Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting  Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.
Jennifer F. Kawwass, M. D. , Sara Crawford, Ph. D. , Donna R
Assessment of luteinizing hormone level in the gonadotropin-releasing hormone antagonist protocol  Georg Griesinger, M.D., Anja Dawson, M.D., Askan Schultze-Mosgau,
Aaron K. Styer, M. D. , Diane L. Wright, Ph. D. , H. C. L. D. , Anne M
Live babies born per oocyte retrieved in a subpopulation of oocyte donors with repetitive reproductive success  J. Ryan Martin, M.D., Jason G. Bromer,
Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series  Nanette L. Rollene,
Are endometrial parameters by three-dimensional ultrasound and power Doppler angiography related to in vitro fertilization/embryo transfer outcome?  Luis.
Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men  Subodhsingh Chauhan, M.D.,
Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization  David W. Schmidt, M.D.,,
Failed IVF cycles and the risk of subsequent preeclampsia or fetal growth restriction: a case-control exploratory study  Ioanna Tsoumpou, M.D., Ahmed.
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.
Cost-effectiveness comparison between pituitary down-regulation with a gonadotropin- releasing hormone agonist short regimen on alternate days and an antagonist.
Eric S. Surrey, M. D. , Debra A. Minjarez, M. D. , John M. Stevens, B
Current evaluation of amenorrhea
David H. Barad, M.D., M.S., Norbert Gleicher, M.D. 
Transfer of two versus three embryos in women less than 40 years old undergoing frozen transfer cycles  Inna Berin, M.D., Lawrence L. Engmann, M.D., Claudio.
Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists 
Aline Ketefian, M. D. , Jianfang Hu, Ph. D. , Alfred A. Bartolucci, Ph
Comparison of a gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare-up regimen in poor responders undergoing ovarian stimulation 
Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study  Ahmed Badawy, M.D., Aboubakr.
Krinos M. Trokoudes, M. D. , Constantinos Pavlides, M. Sc
Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy  Eman A. Elgindy,
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.
Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.
In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation 
Logarithmic curves depicting initial level and rise of serum beta human chorionic gonadotropin and live delivery outcomes with in vitro fertilization:
Not all twins are monozygotic after elective single embryo transfer: analysis of 32,600 elective single embryo transfer cycles as reported to the Society.
Presentation transcript:

Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted reproductive technology: a retrospective study with 2,555 fresh embryo transfers  Robert Ochsenkühn, M.D., Andrea Arzberger, M.D., Viktoria von Schönfeldt, Ph.D., Julia Gallwas, M.D., Nina Rogenhofer, M.D., Alexander Crispin, M.D., Christian J. Thaler, M.D., Ulrich Noss, M.D.  Fertility and Sterility  Volume 98, Issue 2, Pages 347-354 (August 2012) DOI: 10.1016/j.fertnstert.2012.04.041 Copyright © 2012 American Society for Reproductive Medicine Terms and Conditions

Figure 1 (A) All cycles (n = 2,055): live birth rates are significantly lower in group 3 as compared with group 1 (P=.012) and group 2 (P=.007). (B) Gonadotropin-releasing hormone agonist cycles (n = 2,062): live birth rates are significantly lower in group 3 as compared with group 1 (P=.034) and group 2 (P=.01). (C) Gonadotropin-releasing hormone antagonist cycles (n = 493): There are no significant differences between the P groups. Fertility and Sterility 2012 98, 347-354DOI: (10.1016/j.fertnstert.2012.04.041) Copyright © 2012 American Society for Reproductive Medicine Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.